ARS Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

ARS Pharmaceuticals

28/10/2023 03:03

* ARS Pharmaceuticals Inc  SPRY.OQ   SPRY.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for ARS Pharmaceuticals
Inc
is for a loss of 18 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ARS
Pharmaceuticals Inc is $4​, above​ its last closing price
of $3.47. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.19       -0.17      -0.18     Missed  -3.6
 Mar. 31 2023  -0.17       -0.17      -0.16     Beat    4.6
 Dec. 31 2022  -0.13       -0.13      0.77      Beat    692.3​
 Sep. 30 2022  -0.35       -0.35      -0.50     Missed  -40.8
 ​​Jun.        -0.50       -0.48      -0.55     Missed  -13.8
 30 2022                                                
 Mar. 31 2022  -0.53       -0.54      -0.70     Missed  -30.6​
 Dec. 31 2021              -0.70      -0.67     Beat    4.6
 Sep. 30 2021  -0.69       -0.67      -0.65     Beat    3.6
 This summary was machine generated October 28 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated